Src-dependent DBL family members drive resistance to vemurafenib in human melanoma

The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a BRAF(V600E) mutation. Unfortunately, the majority of patients eventually develop drug-resistant disease. We employed a genetic screening approach to identify gain-o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Res
Asıl Yazarlar: Feddersen, Charlotte R., Schillo, Jacob L., Varzavand, Afshin, Vaughn, Hayley R., Wadsworth, Lexy S., Voigt, Andrew P., Zhu, Eliot Y., Jennings, Brooke M., Mullen, Sarah A., Bobera, Jeremy, Riordan, Jesse D., Stipp, Christopher S., Dupuy, Adam J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6774858/
https://ncbi.nlm.nih.gov/pubmed/31416844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-0244
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller